Trials / Recruiting
RecruitingNCT03713424
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University of Missouri-Columbia · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clavulanic Acid | Beta lactamase inhibitor for smoking cessation |
| DRUG | Placebo oral capsule | placebo |
Timeline
- Start date
- 2019-03-26
- Primary completion
- 2026-08-31
- Completion
- 2026-08-31
- First posted
- 2018-10-19
- Last updated
- 2025-10-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03713424. Inclusion in this directory is not an endorsement.